Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 99

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 99
---
 even if we enter into
a collaboration involving any of our drug and diagnostics technology candidates, the arrangement will be subject to numerous risks, which
may include the following:

| ● | the collaborators will likely have significant discretion in                   
 determining the efforts and resources that they will apply to a collaboration; |

| ● | the collaborator may ultimately choose not pursue development                                                                                 
 and commercialization of our drug or diagnostics technology candidates or may elect not to continue or renew development or commercialization 
 programs, based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability         
 of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;                 |

| ● | the collaborator may delay clinical trials, provide insufficient                                                                        
 funding for a clinical trial, stop a clinical trial, abandon a drug or diagnostics technology candidate, repeat or conduct new clinical 
 trials, or require a new formulation of a drug or diagnostics technology candidate for clinical testing;                                |

| ● | the collaborator could independently develop, or develop with                                   
 unrelated parties, drugs that compete directly or indirectly with our drugs or drug candidates; |

| ● | the collaborator with marketing and distribution rights to one                         
 or more drugs may not commit sufficient resources to their marketing and distribution; |

| ● | the collaborator may not properly maintain or defend our IP                                                                           
 rights or may use our IP or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize 
 or invalidate our IP or proprietary information or expose us to potential liability;                                                  |

| ● | disputes may arise between us and the collaborator that cause                                                                         
 the delay or termination of the research, development or commercialization of our drug and diagnostics technology candidates, or that 
 result in costly litigation or arbitration that diverts management attention and resources;                                           |

| ● | the collaboration may be terminated and, if terminated, may                                                                             
 result the Company needing additional capital to pursue further development or commercialization of the applicable drug and diagnostics 
 technology candidates;                                                                                                                  |

<div align='center'>52</div>

| ● | the collaborator may own or co-own IP covering our drugs that                                                                
 results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such IP; |

| ● | the collaboration may result in increased operating expenses     
 or the assumption of indebtedness or contingent liabilities; and |

| ● | the collaboration arrangement may result in the loss of key                        
 personnel